regulatory
confidence high
sentiment neutral
materiality 0.70
Sesen Bio gets Nasdaq exception to complete Carisma merger by March 10; delisting risk if not compliant
Carisma Therapeutics Inc.
- Nasdaq Panel granted exception from $1.00 bid price rule to complete merger with Carisma by March 10, 2023.
- Special meeting of stockholders on March 2, 2023 to approve merger and reverse stock split.
- If compliance not demonstrated by March 10, common stock will be delisted unless further exception granted.
- Company must demonstrate compliance with all initial listing requirements upon closing of merger.